Neurotoxicity

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
월요일, 4월 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
수요일, 3월 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

Peer-Reviewed Scientific Publication Proposes Unifying Single Toxin Theory of Brain Neurodegeneration that Identifies New Drug Targets and Treatments for Alzheimer’s Disease and Other Neurodegenerative Disorders

Retrieved on: 
화요일, 3월 26, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Brain, DSM-IV codes, APOE4, Patient, Biomarker, NDA, Standard of care, Prion, Doctor of Philosophy, MD, Protein, Neurotoxicity, Genotype, Treatment, Safety, ALS, Canadian International Council, Amyloid

In addition, our single toxin theory of brain neurodegeneration identifies new targets and approaches for the development of disease-modifying treatments,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • In addition, our single toxin theory of brain neurodegeneration identifies new targets and approaches for the development of disease-modifying treatments,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • The application of biomarkers, in particular p-tau, synaptic markers, and brain volumetrics for the evaluation of disease course and therapeutic efficacy in AD trials.
  • Other neurodegenerative disorders follow the same pattern of protein dysregulation, impaired clearance, and increased aggregation, leading to neurotoxicity and loss of function.
  • In these diseases, a normal essential protein starts accumulating in the brain, misfolding and aggregating into soluble oligomers.

NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

Retrieved on: 
월요일, 3월 25, 2024
Suicide, Depression, Conference, HOPE, Science, NMDA, Patient, CNS, Efficacy, Therapy, Risk, Neurotoxicity, Spectrum, PTSD, Pharmaceutical industry

RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.

Key Points: 
  • RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
  • The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders.
  • Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced."
  • "HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality.

EQS-News: Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
수요일, 3월 13, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
금요일, 3월 8, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
목요일, 3월 7, 2024
Shareholder, Autoimmune disease, Research, Messenger, FDA, Randomness, Food, Neurotoxicity, Cytokine release syndrome, Risk, Autoantibody, BCMA, Lupus, Safety, Therapy, Fatigue, Pharmacokinetics, Muscle weakness, Multiple myeloma, Myasthenia gravis, SLE, IND, CGMP, Concurrency, Pharmaceutical industry

GAITHERSBURG, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the full year ended December 31, 2023, and recent corporate updates.

Key Points: 
  • Enrollment remains ongoing in the Company’s Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MG (NCT04146051), with topline results expected in mid-2024.
  • Announced Positive Long-Term Follow-Up Data from Phase 2a Study of Descartes-08 in Patients with MG.
  • In January 2024, Cartesian announced that the FDA cleared its IND application for Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T product candidate.
  • General and administrative expenses were $40.6 million for the year ended December 31, 2023, compared to $23.9 million for the year ended December 31, 2022.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
수요일, 2월 28, 2024
Research, Doctor of Philosophy, General partnership, Drug development, Growth, Frustration, University, Chronic pain, SUNY, Biomedical sciences, Epilepsy, Neurology, Rett syndrome, Smith, Kline & French, Acadia Pharmaceuticals, School, University at Buffalo, Biotechnology, ATyr Pharma, Health, Neurotoxicity, Cell, Therapy, DSM-IV codes, Brain, Neuropharmacology, Proteostasis, Amathus, Record, Drug discovery, Peripheral neuropathy, MPS, Physics, OPKO Health, Genomics, Acquisition, EMD, LoDo, Denver, MD, Organoid, Multiple sclerosis, Prevalence, Brown University, Brandeis University, Serono, Patient, Disease, GSK plc, Pharmaceutical industry

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
화요일, 2월 27, 2024
Nerve, Central nervous system, Metabolism, PXR, Alzheimer's disease, Testosterone, PCN, Research, MSI, Diabetic cardiomyopathy, Inflammation, Pathology, Deficit spending, Pregnane X receptor, MALDI, Neurotoxicity, Dysbiosis, JPA, Hippocampus, CYP, Heart failure, DCM, Domestic airport, Phenytoin, Mass spectrometry, PHT, Triglyceride, TMAO, Transplant, Glucocorticoid, Lipid metabolism, Patient, Journal, Glucose, Heart, Mouse, Glycated hemoglobin, Brain

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
화요일, 2월 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.